Efficacy of EGFR tyrosine kinase inhibitors in patients having EGFR-activating mutations with or without BIM polymorphisms

被引：0
|
作者：
Ryo Ariyasu
Noriko Yanagitani
Kenichi Tadokoro
Toshikazu Yamaguchi
Ken Uchibori
Satoru Kitazono
Naoya Fujita
Ryohei Katayama
Makoto Nishio
机构：
[1] The Cancer Institute Hospital,Department of Thoracic Medical Oncology
[2] Japanese Foundation for Cancer Research,Cancer Chemotherapy Center
[3] BML,undefined
[4] INC,undefined
[5] Japanese Foundation for Cancer Research,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2020年 / 86卷
关键词：
deletion polymorphism; single nucleotide polymorphism; Non-small cell lung cancer; EGFR-TKI;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：517 / 525
页数：8
相关论文
共 50 条
  • [31] EXON 19 DELETIONS, SMOKING HISTORY AND GENDER AS ADDITIONAL PREDICTIVE FACTORS FOR TREATMENT BENEFIT WITH EGFR TYROSINE KINASE INHIBITORS IN PATIENTS HARBOURING ACTIVATING EGFR MUTATIONS: A META-ANALYSIS OF 1432 PATIENTS IN SIX RANDOMISED TRIALS
    Ding, Pei Ni
    Gralla, Richard
    Inoue, Akira
    Lord, Sally
    Pavlakis, Nick
    Mitsudomi, Tetsuya
    Links, Matthew
    Gebski, Val
    Yang, James C.
    Lee, Chee Khoon
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S593 - S594
  • [32] Characterization of Acquired Receptor Tyrosine Kinase Fusions as Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors
    Xu, H.
    Shu, Y.
    Jian, H.
    Shen, J.
    Xiang, J.
    Li, H.
    Li, B.
    Zhang, T.
    Zhang, L.
    Mao, X.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S562 - S563
  • [33] Detection of Low-Frequency KRAS Mutations in cfDNA From EGFR-Mutated NSCLC Patients After First-Line EGFR Tyrosine Kinase Inhibitors
    Nardo, Giorgia
    Carlet, Jessica
    Marra, Ludovica
    Bonanno, Laura
    Boscolo, Alice
    Dal Maso, Alessandro
    Boscolo Bragadin, Andrea
    Indraccolo, Stefano
    Zulato, Elisabetta
    FRONTIERS IN ONCOLOGY, 2021, 10
  • [34] Early responses of EGFR circulating tumor DNA to EGFR tyrosine kinase inhibitors in lung cancer treatment
    Imamura, Fumio
    Uchida, Junji
    Kukita, Yoji
    Kumagai, Toru
    Nishino, Kazumi
    Inoue, Takako
    Kimura, Madoka
    Kato, Kikuya
    ONCOTARGET, 2016, 7 (44) : 71782 - 71789
  • [35] Efficacy of EGFR Tyrosine Kinase Inhibitors in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer: A Meta-Analysis of 13 Randomized Trials
    Petrelli, Fausto
    Borgonovo, Karen
    Cabiddu, Mary
    Barni, Sandro
    CLINICAL LUNG CANCER, 2012, 13 (02) : 107 - 114
  • [36] Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors and Therapeutic Approaches: An Update
    Ahsan, Aarif
    LUNG CANCER AND PERSONALIZED MEDICINE: CURRENT KNOWLEDGE AND THERAPIES, 2016, 893 : 137 - 153
  • [37] Uncommon frame-shift exon 19 EGFR mutations are sensitive to EGFR tyrosine kinase inhibitors in non-small cell lung carcinoma
    Giuseppina Improta
    Angela Zupa
    Maria Iole Natalicchio
    Lorenza Sisinni
    Anna Marinaccio
    Giovanni Bozza
    Giulia Vita
    Michele Aieta
    Matteo Landriscina
    Medical Oncology, 2018, 35
  • [38] Uncommon frame-shift exon 19 EGFR mutations are sensitive to EGFR tyrosine kinase inhibitors in non-small cell lung carcinoma
    Improta, Giuseppina
    Zupa, Angela
    Natalicchio, Maria Iole
    Sisinni, Lorenza
    Marinaccio, Anna
    Bozza, Giovanni
    Vita, Giulia
    Aieta, Michele
    Landriscina, Matteo
    MEDICAL ONCOLOGY, 2018, 35 (03)
  • [39] Durable response of lung carcinoma patients to EGFR tyrosine kinase inhibitors is determined by germline polymorphisms in some immune-related genes
    Dalens, Lorraine
    Niogret, Julie
    Richard, Corentin
    Chevrier, Sandy
    Foucher, Pascal
    Coudert, Bruno
    Lagrange, Aurelie
    Favier, Laure
    Westeel, Virginie
    Kim, Stefano
    Adotevi, Olivier
    Chapusot, Caroline
    Martin, Laurent
    Arnould, Laurent
    Kaderbhai, Coureche-Guillaume
    Boidot, Romain
    MOLECULAR CANCER, 2023, 22 (01)
  • [40] Clinical Predictors of Response to EGFR Tyrosine Kinase inhibitors in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
    Fukihara, Jun
    Watanabe, Naohiro
    Taniguchi, Hiroyuki
    Kondoh, Yasuhiro
    Kimura, Tomoki
    Kataoka, Kensuke
    Matsuda, Toshiaki
    Yokoyama, Toshiki
    Hasegawa, Yoshinori
    ONCOLOGY, 2014, 86 (02) : 86 - 93
12345